India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.

The Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter.

The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.

Of 31 drugs the Chinese government listed for a pilot bidding program, multinational pharmas landed only two contracts.

Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.

A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.

Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that…

The Justice Department will no longer pursue a whistleblower case against Gilead for using an unapproved API in some HIV drugs.